On October 18, 2021 Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, reported that Professor Brian Berman, M.D., Ph.D., Professor Emeritus, Dermatology and Dermatologic Surgery, University of Miami will be giving a talk on the clinical study result of the Company’s lead drug candidate, STP705, at the 2021 Fall Clinical Dermatology Conference, as the principal investigator (Press release, Sirnaomics, OCT 18, 2021, View Source [SID1234591459]). The Company will also exhibit a poster at the conference highlighting results from a Phase IIa clinical trial of STP705 for the treatment of cutaneous squamous cell carcinoma in situ (nonmelanoma skin cancer). The hybrid conference is taking place in person at the Wynn Las Vegas hotel in Las Vegas, NV, USA from October 21-24, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Talk: New and Future Innovations in Dermatologic Care
Title: Advances in Therapeutic Technology: STP705 siRNA for in situ Squamous Cell Carcinoma
Presenter: Brian Berman, M.D., Ph.D., Professor Emeritus, Dermatology and Dermatologic Surgery, University of Miami; Co-Director Center for Clinical and Cosmetic Research, Aventura, FL, USA
Overview: Clinical trial results showing STP705, used to target TGF-β1 and COX-2 siRNAs for the treatment of nonmelanoma skin cancer, has demonstrated rates of histological clearance that rival surgical excision combined with improved cosmetic appearance.
Date and Time: October 21, 2021, from 10:20 AM to 10:55 AM PT
Location: Wynn Las Vegas,Cristal 2, 4, 6
Poster:
Title: Open Label, Phase I/II, Dose Escalation Study to Evaluate Safety and Efficacy of Intralesional Injection of a TGF-β1/COX-2 dual targeting small interfering (si)RNA therapeutic, in Adult Patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC)
Date and Time: October 21, 2021, from 7:00 AM to 4:30 PM PT; October 22, 2021, from 7:00 AM to 12:30 PM PT
Location: Wynn Las Vegas,Cristal 1, 3, 5